Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 16/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.36 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5537370 | 0.96 | F10 (0.37) | F10SMN1; SMN2TDP1KCNH2KLKB1 | |
| SCHEMBL5553897 | 0.91 | F10 (0.41) | F10SMN1; SMN2TDP1KCNH2NPC1 | |
| SCHEMBL5538284 | 0.91 | F10 (0.40) | F10KCNH2KLKB1NPC1ALOX15 | |
| SCHEMBL5532157 | 0.87 | F10 (0.43) | F10KCNH2KLKB1 | |
| SCHEMBL5541024 | 0.86 | F10 (0.38) | F10KCNH2KLKB1NPC1ALOX15 | |
| SCHEMBL5534065 | 0.86 | F10 (0.41) | F10SMN1; SMN2TDP1NPC1HTT | |
| SCHEMBL5533806 | 0.86 | F10 (0.33) | F10 | |
| SCHEMBL5531606 | 0.85 | F10 (0.47) | F10SMN1; SMN2TDP1KCNH2KLKB1 | |
| SCHEMBL5555126 | 0.85 | F10 (0.40) | F10SMN1; SMN2KCNH2NPC1ALOX15 | |
| SCHEMBL5555100 | 0.85 | F10 (0.46) | F10KCNH2KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030069250-A1 | Benzamide inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. | 2003-04-10 | — | — | US | claimed |
| US-7312235-B2 | Benzamide inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| EP-1373194-B1 | BENZAMIDE INHIBITORS OF FACTOR Xa | MILLENNIUM PHARM INC (US) | 2007-08-01 | — | — | EP | disclosed |
| EP-1373194-A1 | BENZAMIDE INHIBITORS OF FACTOR Xa | Millennium Pharmaceuticals, Inc. (US) | 2004-01-02 | — | — | EP | disclosed |
| US-20030069250-A1 | Benzamide inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. | 2003-04-10 | — | — | US | disclosed |
| WO-2002079145-A1 | BENZAMIDE INHIBITORS OF FACTOR Xa | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2002-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030069250-A1 | Benzamide inhibitors of factor Xa | SERPINC1, TFPI, F12 | F10 10/4885SMN1; SMN2 2492/4885TDP1 1161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.